Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Vomiting 39Nausea 31Neoplasms 10Breast Neoplasms 10Lymphoma 9Multiple Myeloma 7Ovarian Neoplasms 6Lymphoma, Non-Hodgkin 6Leukemia, Myeloid, Acute 6Sezary Syndrome 4Myeloproliferative Disorders 4Leukemia 4Pruritus 3Primary Myelofibrosis 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Pdgfra-Associated Chronic Eosinophilic Leukemia 3Neoplasms, Plasma Cell 3Myelodysplastic Syndromes 3Mycosis Fungoides 3Lymphoma, T-Cell, Cutaneous 3Lymphoma, Mantle-Cell 3Lymphoma, Large-Cell, Immunoblastic 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma, Follicular 3Lymphoma, B-Cell, Marginal Zone 3Leukemia, Neutrophilic, Chronic 3Leukemia, Myelomonocytic, Chronic 3Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 3Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3Leukemia, Lymphocytic, Chronic, B-Cell 3

Interventions

Magnetic Resonance Spectroscopy 17Iodine-131 16lenvatinib 13trametinib 12Thyrotropin Alfa 11Sorafenib 11pembrolizumab 10dabrafenib 10Paclitaxel 9vandetanib 8Thyroxine 8Surgical Procedures, Operative 7Sunitinib 7selpercatinib 6cabozantinib 6Nivolumab 6Fluorodeoxyglucose F18 6Everolimus 6pazopanib 5Vemurafenib 5Thyroidectomy 5Specimen Handling 5Saline Solution 5Radiotherapy 5Radiofrequency Ablation 5Cyclophosphamide 5Cisplatin 5Biopsy 5apatinib 4anlotinib 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Thyroid Neoplasms × Aprepitant × Clear all
NCT06697782 2025-01-22

Aprepitant and Ondansetron Monotherapy or Combination for Postoperative Nausea and Vomiting in Thyroid Cancer

The First Affiliated Hospital of Zhengzhou University

Phase 4 Completed
600 enrolled
Head & Neck

Thyroid Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡